Physician profile
Gregory Bernath
NPI 1497749873
$4,912.14
in general payments reported to CMS, 2019-2025
12 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $321 · 2021: $385 · 2022: $477 · 2023: $2,121 · 2024: $465 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,227 · Travel and Lodging: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.44 |
| Travel and Lodging | $903.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,488.98 | 2021-2025 | Telescope, Onyx Frontier, Ffrangio |
| Medtronic Vascular, INC. | $673.32 | 2019-2020 | |
| Cvrx, INC. | $159.67 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $158.60 | 2019 | |
| Shockwave Medical, INC | $132.41 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $85.06 | 2025 | Repatha |
| Abiomed | $61.90 | 2019-2024 | Impella |
| Abbott Laboratories | $55.20 | 2020 | |
| Cleerly, INC. | $34.24 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Bridgebio Pharma, INC. | $25.86 | 2025 | Attruby |
| Terumo Medical Corporation | $23.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bernath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.